CSL Behring’s Hemgenix granted first ever direct access in France for haemophilia B gene therapy

13 December 2023 - CSL Behring has been granted Direct Access for Hemgenix (etranacogene dezaparvovec) by the French Ministry of ...

Read more →

Amylyx Pharmaceuticals provides update on Accès Compassionnel for AMX0035 in France

5 October 2023 - L’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), the national authority for ...

Read more →

Do France, Germany, and Italy agree on the added therapeutic value of medicines?

17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...

Read more →

Patient and citizen participation at the organisational level in health technology assessment: an exploratory study in five jurisdictions

8 August 2023 - While patient participation in individual health technology assessments has been frequently described in the literature, patient and ...

Read more →

Santhera concludes agreement with French authorities on Raxone reimbursement and plans to submit a request for an early access program for vamorolone

8 February 2023 - Santhera Pharmaceuticals announces that it has secured a final reimbursement agreement with the French authorities related to ...

Read more →

HAS updates its recommendations for the proper use of osteoporosis drugs

24 January 2023 - Osteoporosis is a disease whose first cause is ageing and which is characterised by the reduction ...

Read more →

Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2

30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...

Read more →

COVID-19: a global opinion on bivalent vaccines in mid-September

5 September 2022 - The EMA has just modified the marketing authorisations granted to messenger RNA vaccines developed by Moderna and ...

Read more →

Monkeypox: a preventive vaccination offered to those most at risk of exposure

8 July 2022 - Faced with the spread of the Monkeypox virus, the kinetics of the epidemic and the difficulties of ...

Read more →

HAS clarifies the framework for use of Xevudy

29 April 2022 -  After authorising early access to Xevudy (sotrovimab) as a curative treatment for COVID-19 on 6 January, HAS ...

Read more →

HAS decides in favour of reimbursement of Paxlovid

25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...

Read more →

Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients

20 April 2022 - The opinion by the Transparency Commission follows after Idefirix was granted a funded Early Access Program by ...

Read more →

Cystic fibrosis: early access granted to the Kaftrio/Kalydeco combination

29 March 2022 - The High Authority for Health has authorised early access to a first treatment for children aged 6 ...

Read more →

COVID-19: a second booster reserved for those most at risk

18 March 2022 - While the COVID-19 epidemic seems to be on the rise again after a few weeks of decline, ...

Read more →

COVID-19: early access granted to Paxlovid as a curative treatment

21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...

Read more →